A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies
Sharp, A. Williams, A. Blagden, S. P. Plummer, E. R. Hochhauser, D. Krebs, Matthew G Pacey, S. Evans, T. R. J. Whelan, S. Nandakumar, S.
Sharp, A.
Williams, A.
Blagden, S. P.
Plummer, E. R.
Hochhauser, D.
Krebs, Matthew G
Pacey, S.
Evans, T. R. J.
Whelan, S.
Nandakumar, S.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Sharp A, Williams A, Blagden SP, Plummer ER, Hochhauser D, Krebs M, et al. A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680304856.